[go: up one dir, main page]

Siegall et al., 1989 - Google Patents

Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin

Siegall et al., 1989

View PDF
Document ID
14753260054636983940
Author
Siegall C
Chaudhary V
FitzGerald D
Pastan I
Publication year
Publication venue
Journal of Biological Chemistry

External Links

Snippet

Pseudomonas exotoxin is composed of three structural domains that are responsible for cell recognition, membrane translocation, and ADP-ribosylation. The substitution of the cell recognition domain (domain Ia) with a growth factor such as transforming growth factor α …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48376—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/48384—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/48415—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/48438—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a toxin
    • A61K47/48484—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a toxin the drug being a bacterial toxin, e.g. diphteria toxin, Pseudomonas exotoxin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Similar Documents

Publication Publication Date Title
Siegall et al. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin
EP0531434B1 (en) Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
DE69529517T2 (en) CIRCULAR PERMUTED LIGANDS AND CIRCULAR PERMUTED CHIMERIC MOLECULES
Kreitman et al. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor
EP2332970B1 (en) Mutated pseudomonas exotoxins with reduced antigenicity
Siegall et al. Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin
US5821238A (en) Recombinant pseudomonas exotoxin with increased activity
JP2848489B2 (en) Recombinant Pseudomonas exotoxin: Structure of active immunotoxin with low side effects
Chaudhary et al. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.
Batra et al. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR (Fv)-PE40 and DT388-anti-TFR (Fv)
US5990296A (en) Single chain B3 antibody fusion proteins and their uses
Kreitman et al. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds
US5863745A (en) Recombinant antibody-toxin fusion protein
US5082927A (en) Selectively cytotoxic IL-4-PE40 fusion protein
JPH04501051A (en) Recombinant DNA-derived Bordetella toxin subunit analog
JPH0829101B2 (en) Recombinant antibody-toxin fusion protein
AU675413B2 (en) Recombinant immunotoxins
Joshi et al. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli
Siegall et al. Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation
Hambali The periplasmic expression of recombinant human epidermal growth factor (hEGF) in Escherichia coli
Kreitman et al. Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor. alpha. within Pseudomonas exotoxin as a targeting ligand
JPH07278200A (en) Antitumor protein containing pe40ab
Debinski et al. Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor a and Pseudomonas exotoxin
Niv et al. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy
US20070167610A1 (en) Recombinant soluble adenovirus receptor